O	0	1	A
O	2	12	Randomized
O	13	18	Trial
O	19	21	of
B-intervention	22	32	Mometasone
I-intervention	33	40	Furoate
O	41	42	0
O	42	43	.
O	43	44	1
O	44	45	%
O	46	48	to
O	49	55	Reduce
O	56	60	High
O	60	61	-
O	61	66	Grade
B-condition	67	72	Acute
I-condition	73	82	Radiation
I-condition	83	93	Dermatitis
O	94	96	in
O	97	103	Breast
O	104	110	Cancer
O	111	119	Patients
O	120	129	Receiving
O	130	144	Postmastectomy
O	145	154	Radiation
O	154	155	.

O	156	157	A
O	158	159	2
O	159	160	-
O	160	163	arm
O	163	164	,
O	165	171	double
O	171	172	-
O	172	179	blinded
O	180	190	randomized
O	191	196	trial
O	197	200	was
O	201	210	conducted
O	211	213	to
O	214	222	evaluate
O	223	226	the
O	227	235	efficacy
O	236	238	of
O	239	240	0
O	240	241	.
O	241	242	1
O	242	243	%
O	244	254	mometasone
O	255	262	furoate
O	263	264	(
O	264	266	MF
O	266	267	)
O	268	274	versus
B-control	275	282	Eucerin
I-control	283	291	Original
I-control	292	293	(
I-control	293	294	E
I-control	294	295	)
O	296	301	cream
O	302	304	in
O	305	315	preventing
O	316	319	the
O	320	331	development
O	332	334	of
O	335	343	moderate
O	344	346	to
O	347	353	severe
O	354	359	acute
O	360	369	radiation
O	370	380	dermatitis
O	381	382	(
O	382	385	ARD
O	385	386	)
O	387	389	in
O	390	396	breast
O	397	403	cancer
O	404	412	patients
O	413	422	receiving
O	423	437	postmastectomy
O	438	447	radiation
O	448	449	(
O	449	453	PMRT
O	453	454	)
O	454	455	.

B-eligibility	456	462	Breast
I-eligibility	463	469	cancer
I-eligibility	470	478	patients
I-eligibility	479	489	undergoing
I-eligibility	490	495	chest
I-eligibility	496	500	wall
I-eligibility	501	505	with
I-eligibility	506	508	or
I-eligibility	509	516	without
I-eligibility	517	522	nodal
I-eligibility	523	532	radiation
I-eligibility	533	540	therapy
O	541	542	(
O	542	544	RT
O	544	545	)
O	546	547	(
O	547	549	50
O	550	552	Gy
O	552	553	)
O	554	558	were
O	559	567	eligible
O	567	568	.

O	569	582	Randomization
O	583	584	(
O	584	585	1
O	585	586	:
O	586	587	1
O	587	588	)
O	589	592	was
O	593	595	to
O	596	598	MF
O	599	601	or
O	602	603	E
O	603	604	,
O	605	612	applied
O	613	618	twice
O	619	624	daily
O	625	629	from
O	630	633	day
O	634	635	1
O	636	638	of
O	639	643	PMRT
O	644	646	to
O	647	649	14
O	650	654	days
O	655	660	after
O	661	665	PMRT
O	665	666	.

O	667	675	Patients
O	676	680	were
O	681	691	stratified
O	692	694	by
O	695	697	RT
O	698	707	technique
O	707	708	,
O	709	713	body
O	714	718	mass
O	719	724	index
O	724	725	,
O	726	729	and
O	730	744	reconstruction
O	745	751	status
O	751	752	.

O	753	758	Daily
O	759	764	bolus
O	765	767	of
O	768	769	3
O	770	772	to
O	773	775	10
O	776	778	mm
O	779	782	was
O	783	790	applied
O	791	793	in
O	794	797	all
O	798	806	patients
O	806	807	.

O	808	811	The
O	812	819	primary
O	820	828	endpoint
O	829	832	was
O	833	836	the
B-outcome-Measure	837	848	development
I-outcome-Measure	849	851	of
I-outcome-Measure	852	860	provider
I-outcome-Measure	860	861	-
I-outcome-Measure	861	869	assessed
I-outcome-Measure	870	875	grade
I-outcome-Measure	876	877	≥
I-outcome-Measure	877	878	2
O	879	880	(
O	880	886	Common
O	887	898	Terminology
O	899	907	Criteria
O	908	911	for
O	912	919	Adverse
O	920	926	Events
O	927	934	version
O	935	936	4
O	936	937	.
O	937	939	03
O	939	940	)
O	941	944	ARD
O	945	949	with
O	950	955	moist
O	956	968	desquamation
O	969	971	or
B-outcome-Measure	972	975	any
I-outcome-Measure	976	981	grade
I-outcome-Measure	982	983	≥
I-outcome-Measure	983	984	3
I-outcome-Measure	985	995	dermatitis
O	995	996	.

O	997	1006	Secondary
O	1007	1016	endpoints
O	1017	1021	were
B-outcome-Measure	1022	1026	time
I-outcome-Measure	1027	1029	to
I-outcome-Measure	1030	1040	occurrence
I-outcome-Measure	1041	1043	of
I-outcome-Measure	1044	1051	maximum
I-outcome-Measure	1051	1052	-
I-outcome-Measure	1052	1057	grade
I-outcome-Measure	1058	1068	dermatitis
O	1069	1072	and
B-outcome-Measure	1073	1080	patient
I-outcome-Measure	1080	1081	-
I-outcome-Measure	1081	1089	reported
I-outcome-Measure	1090	1094	skin
I-outcome-Measure	1095	1103	symptoms
O	1104	1109	using
O	1110	1111	a
O	1112	1116	skin
O	1116	1117	-
O	1117	1124	related
O	1125	1132	quality
O	1133	1135	of
O	1136	1140	life
O	1141	1154	questionnaire
O	1154	1155	,
O	1156	1163	Skindex
O	1163	1164	-
O	1164	1166	16
O	1166	1167	.

O	1168	1179	Assessments
O	1180	1184	were
O	1185	1194	performed
O	1195	1197	at
O	1198	1206	baseline
O	1206	1207	,
O	1208	1214	weekly
O	1215	1221	during
O	1222	1226	PMRT
O	1226	1227	,
O	1228	1231	and
O	1232	1233	2
O	1234	1239	weeks
O	1240	1245	after
O	1246	1250	PMRT
O	1250	1251	.

B-total-participants	1252	1255	124
O	1256	1264	patients
O	1265	1269	were
O	1270	1278	enrolled
O	1279	1286	between
O	1287	1290	May
O	1291	1295	2013
O	1296	1299	and
O	1300	1308	February
O	1309	1313	2016
O	1313	1314	.

O	1315	1317	Of
O	1318	1323	those
O	1323	1324	,
O	1325	1327	35
O	1327	1328	%
O	1329	1332	had
O	1333	1343	pathologic
O	1344	1349	stage
O	1350	1353	III
O	1354	1361	disease
O	1361	1362	,
O	1363	1364	6
O	1364	1365	%
O	1366	1369	had
O	1370	1374	cT4d
O	1375	1382	disease
O	1382	1383	,
O	1384	1387	and
O	1388	1390	68
O	1390	1391	%
O	1392	1401	underwent
O	1402	1416	reconstruction
O	1416	1417	.

O	1418	1423	Sixty
O	1424	1431	percent
O	1432	1440	received
O	1441	1442	3
O	1442	1443	-
O	1443	1454	dimensional
O	1455	1464	conformal
O	1465	1467	RT
O	1468	1472	with
O	1473	1480	photons
O	1481	1485	only
O	1486	1488	to
O	1489	1492	the
O	1493	1498	chest
O	1499	1503	wall
O	1503	1504	,
O	1505	1507	18
O	1507	1508	%
O	1509	1517	received
O	1518	1527	electrons
O	1528	1531	and
O	1532	1539	photons
O	1539	1540	,
O	1541	1544	and
O	1545	1547	23
O	1547	1548	%
O	1549	1557	received
O	1558	1565	inverse
O	1565	1566	-
O	1566	1573	planned
O	1574	1583	intensity
O	1584	1593	modulated
O	1594	1596	RT
O	1596	1597	.

O	1598	1604	Groups
O	1605	1609	were
O	1610	1614	well
O	1615	1623	balanced
O	1624	1627	for
O	1628	1631	age
O	1631	1632	,
O	1633	1637	skin
O	1638	1642	type
O	1642	1643	,
O	1644	1647	and
O	1648	1653	stage
O	1653	1654	.

O	1655	1658	The
B-outcome	1659	1663	rate
I-outcome	1664	1666	of
I-outcome	1667	1672	moist
I-outcome	1673	1685	desquamation
O	1686	1689	was
O	1690	1692	54
O	1692	1693	.
O	1693	1694	8
O	1694	1695	%
O	1696	1698	in
O	1699	1702	the
O	1703	1709	entire
O	1710	1716	cohort
O	1716	1717	,
O	1718	1722	with
O	1723	1724	a
O	1725	1738	significantly
O	1739	1746	reduced
O	1747	1756	incidence
O	1757	1759	in
O	1760	1763	the
O	1764	1766	MF
O	1767	1770	arm
O	1771	1775	than
O	1776	1778	in
O	1779	1782	the
O	1783	1784	E
O	1785	1788	arm
O	1789	1790	(
B-iv-bin-percent	1790	1792	43
I-iv-bin-percent	1792	1793	.
I-iv-bin-percent	1793	1794	8
I-iv-bin-percent	1794	1795	%
O	1796	1798	vs
B-cv-bin-percent	1799	1801	66
I-cv-bin-percent	1801	1802	.
I-cv-bin-percent	1802	1803	7
I-cv-bin-percent	1803	1804	%
O	1804	1805	;
O	1806	1807	P
O	1808	1809	=
O	1810	1811	.
O	1811	1814	012
O	1814	1815	)
O	1815	1816	.

O	1817	1820	The
O	1821	1823	MF
O	1824	1827	arm
O	1828	1831	had
O	1832	1833	a
O	1834	1839	lower
B-outcome	1840	1849	incidence
I-outcome	1850	1852	of
I-outcome	1853	1860	maximum
I-outcome	1861	1865	skin
I-outcome	1866	1876	toxicities
O	1877	1878	(
O	1878	1879	P
O	1880	1881	=
O	1882	1883	.
O	1883	1886	036
O	1886	1887	)
O	1888	1891	and
O	1892	1898	longer
B-outcome	1899	1903	time
I-outcome	1904	1906	to
I-outcome	1907	1918	development
I-outcome	1919	1921	of
I-outcome	1922	1927	grade
I-outcome	1928	1929	3
I-outcome	1930	1940	dermatitis
O	1941	1942	(
B-iv-cont-mean	1942	1944	46
I-iv-cont-mean	1945	1949	days
O	1950	1952	vs
B-cv-cont-mean	1953	1955	35
I-cv-cont-mean	1955	1956	.
I-cv-cont-mean	1956	1957	5
I-cv-cont-mean	1958	1962	days
O	1962	1963	,
O	1964	1976	respectively
O	1976	1977	;
O	1978	1979	P
O	1980	1981	≤
O	1982	1983	.
O	1983	1986	001
O	1986	1987	)
O	1987	1988	.

O	1989	1994	There
O	1995	1998	was
O	1999	2001	no
O	2002	2012	difference
O	2013	2015	in
B-outcome	2016	2023	patient
I-outcome	2023	2024	-
I-outcome	2024	2032	reported
I-outcome	2033	2037	skin
I-outcome	2038	2046	outcomes
O	2047	2054	between
O	2055	2059	arms
O	2059	2060	.

O	2061	2067	Breast
O	2068	2074	cancer
O	2075	2083	patients
O	2084	2093	receiving
O	2094	2096	MF
O	2097	2103	during
O	2104	2108	PMRT
O	2109	2120	experienced
O	2121	2134	significantly
O	2135	2142	reduced
O	2143	2148	rates
O	2149	2151	of
O	2152	2157	moist
O	2158	2170	desquamation
O	2171	2173	in
O	2174	2184	comparison
O	2185	2189	with
O	2190	2191	a
O	2192	2199	control
O	2200	2205	cream
O	2205	2206	.
